Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tivozanib - AVEO Oncology/Kyowa Kirin

Drug Profile

Tivozanib - AVEO Oncology/Kyowa Kirin

Alternative Names: ASP 4130; AV-951; AVE-951; Fotivda; Kil8951; KRN-951; Tivopath; Tivozanib hydrochloride monohydrate

Latest Information Update: 30 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; AstraZeneca; AVEO Oncology; EUSA Pharma; Institute Gustave-Roussy; Kyowa Kirin; Northwestern University; Pharmstandard
  • Class Antineoplastics; Isoxazoles; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Age-related macular degeneration; Renal cell carcinoma

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II Soft tissue sarcoma
  • Phase I/II Liver cancer
  • Preclinical Age-related macular degeneration
  • Suspended Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Solid tumours

Most Recent Events

  • 18 Nov 2019 Safety and efficacy data from the phase III TIVO-3 trial in Renal cell carcinoma released by AVEO Oncology
  • 04 Nov 2019 AVEO Oncology announces intention to submit NDA to US FDA for Renal cell carcinoma (Second-line therapy or greater, Late-stage disease) in in the first quarter of 2020
  • 23 Sep 2019 EUSA Pharma announces intention to launch tivozanib for Renal cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top